{"id":19489,"date":"2024-04-25T11:11:37","date_gmt":"2024-04-25T09:11:37","guid":{"rendered":"https:\/\/www.priviumfund.com\/?page_id=19489"},"modified":"2026-03-04T16:32:25","modified_gmt":"2026-03-04T15:32:25","slug":"aescap-genetics","status":"publish","type":"page","link":"https:\/\/www.priviumfund.com\/zh\/aescap-genetics\/","title":{"rendered":"Aescap Genetics"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"19489\" class=\"elementor elementor-19489\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c0afe70 e-flex e-con-boxed e-con e-parent\" data-id=\"c0afe70\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c407f76 elementor-widget__width-initial elementor-tabs-view-horizontal elementor-widget elementor-widget-tabs\" data-id=\"c407f76\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"tabs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-tabs\">\n\t\t\t<div class=\"elementor-tabs-wrapper\" role=\"tablist\" >\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-2051\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-2051\" aria-expanded=\"false\">About<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-2052\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2052\" aria-expanded=\"false\">Latest Report<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-2053\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2053\" aria-expanded=\"false\">Request Information<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-2054\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2054\" aria-expanded=\"false\">Sustainability-related Disclosures<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-2055\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2055\" aria-expanded=\"false\">Fund Documents<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<div class=\"elementor-tabs-content-wrapper\" role=\"tablist\" aria-orientation=\"vertical\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-2051\" aria-expanded=\"false\">About<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2051\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-2051\" tabindex=\"0\" hidden=\"false\"><p><span data-contrast=\"auto\"><a href=\"https:\/\/www.aescap.com\" rel=\"nofollow noopener\" target=\"_blank\">Aescap Genetics<\/a>\u00a0<\/span><span data-contrast=\"auto\">invests in the shares of publicly listed genetics biotech \/ life sciences companies. It invests in highly innovative companies that develop and market new genetics medical treatments such as gene, RNA and cell therapies. It can to a limited extent also invest in companies that develop and market medical genetics diagnostics. The<\/span><span data-contrast=\"auto\">\u00a0companies are active in <\/span><span data-contrast=\"auto\">the concept of precision medicine. The concept of precision medicine is based on the fact that people respond differently to the same treatment. Based on gene profiling and biomarker data a patient can be given the right treatment from the start<\/span><span data-contrast=\"auto\">.\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Aescap Genetics<\/span><span data-contrast=\"auto\">\u00a0will typically<\/span><span data-contrast=\"auto\"> construct a focused portfolio, i<\/span><span data-contrast=\"auto\">nvest<\/span><span data-contrast=\"auto\">ing<\/span><span data-contrast=\"auto\"> in <\/span><span data-contrast=\"auto\">approximately 18 <\/span><span data-contrast=\"auto\">companies with the potential to (more than) double their share price over a period of maximum 4-5 years. <\/span><span data-contrast=\"auto\">It<\/span><span data-contrast=\"auto\"> aims to make investments in companies located globally, but most investments are likely to be made in companies located in Europe and Northern America given the innovation power in biotech in these markets.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2052\" aria-expanded=\"false\">Latest Report<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2052\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-2052\" tabindex=\"0\" hidden=\"hidden\"><ul>\n<li><a style=\"font-size: 16px; background-color: #ffffff;\" href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/05\/AescapGen_ARPT_EN.pdf\">Annual Report 2024 Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/08\/AescapGen_SARPT_EN.pdf\">Interim Financial Statements 2024 Aescap Genetics<\/a><\/li>\n<\/ul><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2053\" aria-expanded=\"false\">Request Information<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2053\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"3\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-2053\" tabindex=\"0\" hidden=\"hidden\"><p><script src=\"\/\/js.hsforms.net\/forms\/embed\/v2.js\" type=\"text\/javascript\" charset=\"utf-8\"><\/script><br \/><script>\n  hbspt.forms.create({\n    region: \"na1\",\n    portalId: \"8025090\",\n    formId: \"a4ad4a01-bba5-4322-981a-fd6ea8276803\"\n  });\n<\/script><\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2054\" aria-expanded=\"false\">Sustainability-related Disclosures<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2054\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"4\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-2054\" tabindex=\"0\" hidden=\"hidden\"><p class=\"western\" lang=\"nl-NL\" align=\"right\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><i>Initial publication date: 26 September 2024 (last update: <\/i><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><i>29<\/i><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><i>\u00a0January 2026)<\/i><\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Summary<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b><br \/><\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Aescap Genetics (the <\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b>Fund<\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">)\u00a0aims to create value by investing in publicly traded shares of genetics biotechnology and life sciences companies. The Fund invests in highly innovative companies that develop and market new genetic medical treatments such as gene, RNA and cell therapies. The Fund can, to a limited extent, also invest in companies that develop and market medical genetic diagnostics.\u00a0The Fund\u2019s objective is to achieve an average minimum annual net return (after deduction of costs) of &gt;20 percent over 4-5 years. The Fund will typically invest in companies with the potential to (more than) double their share price over the same period.\u00a0<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Next to the objective of creating a financial return for investors, the Fund also promotes a social characteristic and is therefore classified under article 8 of the Sustainable Finance Disclosure Regulation (<\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b>SFDR<\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">). The main focus of the Fund\u2019s investments is in researching, developing, or producing treatment\/solutions for diseases with a high unmet medical need. A high unmet medical need has been defined as diseases that are characterized by an (inadequacy of) available treatments, which severely impact the patient and the healthcare system, prevalent in the geographies the company currently markets or plans to market or distribute its current or future product(s).\u00a0<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund aims to construct a portfolio of approximately eighteen companies that contribute to the social characteristic, and of which a minimum proportion of 30 percent (of the invested capital of the Fund) are considered sustainable investment. Invested capital consists of the Fund\u2019s assets, excluding cash.\u00a0<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Next to establishing which sustainability risks are considered material for each investee company based on the Sustainability Accounting Standards Board (<\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b>SASB<\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">), the Fund also analyses the investee companies\u2019 preparedness to these sustainability risks as part of its due diligence process. The Fund takes the Principal Adverse Impact (<\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b>PAI<\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">) indicators into account to determine if an investment can be considered sustainable. It investigates the processes and policies of any potential investment on environmental and social risks in the biotechnology sector as defined by the SASB and by the PAI indicators.<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Monitoring of investee companies regarding their Environmental, Social and Governance (<\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b>ESG<\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">) performance takes place monthly based on sustainability risks, investment allocation towards the social characteristic and the proportion of the investments determined as sustainable.<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund engages with investee companies to improve their ESG performance. Engagement can consist of meetings with management, data requests to investor relations to improve the policies and practices, or formal shareholder voting when considered necessary.\u00a0<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund reports on a monthly and quarterly basis with updates on the financial returns. The Fund publishes an annual PAI report highlighting the engagement activities as well as any changes in policies and practices of the investee companies.\u00a0<\/span><\/span><\/p>\n<ul>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_Summary_NL.pdf\">Samenvatting (NL)<\/a><\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_Summary_DK.pdf\">Sammenfatning (DK)<\/a><\/span><\/span><\/li>\n<\/ul>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>No sustainable investment objective<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><br \/>The Fund, promotes a social characteristic but does not have a sustainable investment objective. The Fund aims to have a minimum proportion of 30 percent of sustainable investments that contribute to the social characteristic.<\/span><\/span><\/p>\n<ol>\n<li>\n<p lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund will, in determining the 30 percent proportion of sustainable investments, take the PAI indicators into account. It investigates the processes and policies of any potential investment on environmental and social issues in the biotechnology sector as defined by the SASB and by the PAI indicators.\u00a0The ESG risks that are material to the Fund\u2019s investments are outlined in detail on the Fund manager\u2019s <\/span><\/span><span style=\"color: #467886;\"><u><a href=\"https:\/\/www.priviumfund.com\/zh\/aescap-genetics\/\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">website<\/span><\/span><\/a><\/u><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">.\u00a0In addition, the Fund excludes potential investments with a history of poor performance on sector best practices or that have insufficient policies or plans to improve in their social and environmental impact.\u00a0The fund has prioritized the PAI indicators into\u00a0\u2019very important\u2019 and \u2019important\u2019, respectively, based on their relevancy to the biotechnology sector and the specific areas where a company is most likely to do significant harm. Two of the mandatory PAI indicators are not deemed relevant for the companies within the investment scope of the Fund. The Fund\u2019s PAI statement, available on the Fund manager\u2019s website, contains a detailed explanation of the PAIs considered. If the Fund deems an investment is at risk of having a negative impact on or doing significant harm on more than one of the \u2018very important\u2019 indicators or on five or more of the \u2018important\u2019 indicators, then the investment cannot be considered sustainable. However, it may still contribute to the Fund\u2019s social characteristic.<\/span><\/span><\/p>\n<\/li>\n<li>\n<p lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Each potential investment analysis includes a scan for violations of the\u00a0OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights\u00a0for processes and compliance mechanisms that each investment needs to have.<\/span><\/span><\/p>\n<\/li>\n<\/ol>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">More details can be found in the\u00a0<\/span><\/span><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_PAI_Statement_EN.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #467886;\"><u><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">PAI <\/span><\/span><\/u><\/span><span style=\"color: #467886;\"><u><span style=\"font-family: Calibri, serif;\"><span lang=\"en-US\">Report<\/span><\/span><\/u><\/span><\/a><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">\u00a0and the\u00a0<\/span><\/span><span style=\"color: #467886;\"><u><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_PCD_EN.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">SFDR Pre-Contractual Disclosure (Annex II)<\/span><\/span><\/a><\/u><\/span><span lang=\"en-US\">.<\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Environmental or social characteristics of the financial product<br \/><\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">In addition to the Fund\u2019s financial objective to create value by investing in publicly traded shares of biopharmaceutical, diagnostics and\/or medical device companies, it also promotes a social characteristic. The social characteristic promoted by the Fund consists of the research, development, or production of treatments or solutions for diseases with a high unmet medical need. A high unmet medical need is defined as diseases that are characterized by an (inadequacy of) available treatments, which severely impact the patient and the healthcare system, prevalent in the geographies the investee company currently markets or plans to market or distribute its current or future product(s). Examples are Alzheimer\u2019s disease, arthrosis, diabetes, multiple sclerosis, cancer and Parkinson\u2019s disease.<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund acknowledges the importance of a diverse mix of employees as well as strong corporate controls to develop treatments that work for all patients while maintaining the best working conditions and the highest quality levels in their processes. Therefore, the Fund considers and reports on the gender equality in investee companies\u2019 Boards as well as their internal whistleblower policies. <\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">By reporting on the number of female-identifying Board members and engaging with investee companies to collect this information alongside other employee engagement and diversity information, the sector is encouraged to improve its hiring practices and ultimately benefit from having diverse teams. In addition, by reporting on the level of whistleblower policies and engaging with investee companies to collect this information, the sector is encouraged to foster the best working conditions and the highest quality levels in their medical treatment development processes.<\/span><\/span><\/p>\n<p><span style=\"font-size: 16px;\"> <img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone size-full wp-image-22111\" src=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/10\/241009-AescapGen-SDG-table.jpg\" alt=\"\" width=\"605\" height=\"352\" srcset=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/10\/241009-AescapGen-SDG-table.jpg 605w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/10\/241009-AescapGen-SDG-table-300x175.jpg 300w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/10\/241009-AescapGen-SDG-table-18x10.jpg 18w\" sizes=\"(max-width: 605px) 100vw, 605px\" \/><\/span><strong><br \/><\/strong><\/p>\n<p>More details in the <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_PCD_EN.pdf\" target=\"_blank\" rel=\"noopener\">Pre-Contractual Disclosure Document (Annex II)<\/a><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Investment strategy<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b><br \/><\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund\u00a0invests in shares of publicly listed genetics biotechnology and life sciences companies. It invests in highly innovative companies that develop and market new genetic medical treatments such as gene, RNA and cell therapies. It can, to a limited extent, also invest in companies that develop and market medical genetics diagnostics. The\u00a0investee companies are active in\u00a0the concept of precision medicine. Based on gene profiling and biomarker data a patient can be given the treatment that works best for them specifically. Investee companies can also contribute to the Fund\u2019s social characteristic, namely investing in companies\u00a0researching, developing, or producing treatment\/solutions for diseases with a high unmet medical need.<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund\u00a0has a concentrated portfolio, investing\u00a0in\u00a0approximately eighteen\u00a0companies with the potential to (more than) double their share price over a period of 4-5 years.\u00a0It\u00a0aims to make investments in companies globally, but most investments are likely to be made in companies located in Europe and North America given the innovative power of biotech in these markets.\u00a0<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund\u2019s investment team has a deep knowledge of the biotechnology sector and the ability to understand investee companies from both a financial and ESG perspective.\u00a0The ESG evaluation is used to determine the potential investee company\u2019s preparedness to deal with material ESG risks identified by SASB. If a potential investee company is found to have a low average preparedness on any of the material ESG risks identified, the Fund may include the investment in its portfolio and start an engagement project to improve its preparedness.<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">More details can be found in the\u00a0Fund\u2019s <\/span><\/span><span style=\"color: #467886;\"><u><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/01\/AescapGen_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">prospectus<\/span><\/span><\/a><\/u><\/span><span lang=\"en-US\">.<\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Proportion\u00a0of investments<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b><br \/><\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund aims to align as much of its portfolio as possible with its social characteristic and targets a minimum of 30 percent of the Fund\u2019s invested capital. The Fund\u2019s investments may consist of:<\/span><\/span><\/p>\n<ul>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Listed shares of biopharmaceutical companies and potentially also diagnostics and\/or medical device companies.<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Warrants of such companies. Often these warrants are received as part of an equity issue by a company.<\/span><\/span><\/li>\n<\/ul>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Other Fund holdings may be:<\/span><\/span><\/p>\n<ul>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Cash: the Fund may hold cash freely available for investment or for portfolio management purposes.<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Borrowings: the Fund may temporarily borrow (no longer than one month) up to 10 percent of its Net Asset Value (<\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b>NAV<\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">) for portfolio management purposes or to benefit from an investment opportunity.<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Non-aligned assets: holdings whose activities do not contribute to the social characteristic of the Fund.\u00a0For non-aligned assets, at minimum a material ESG risk analysis based on the SASB is performed.<\/span><\/span><\/li>\n<\/ul>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">More details can be found in the\u00a0Fund\u2019s <\/span><\/span><span style=\"color: #467886;\"><u><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/01\/AescapGen_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">prospectus<\/span><\/span><\/a><\/u><\/span><span lang=\"en-US\">.<\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Monitoring of environmental or social\u00a0characteristics<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b><br \/><\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund has determined that an investment that contributes to the Fund\u2019s promotion of the social characteristic needs to be an investment that is researching, developing, or producing treatment for diseases with a high unmet medical need. The Fund will analyse per investee company what percentage of their activities is related to the research, development or production of drugs for diseases with high unmet medical need.<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund monitors the attainment of the social characteristic through:\u00a0<\/span><\/span><\/p>\n<ul>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">monthly monitoring of investment allocation towards the Fund\u2019s social characteristic\u00a0with the percentage of investee companies researching, developing or producing treatment for diseases with a high unmet medical need;<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">monthly monitoring of the Fund\u2019s exposure to sustainability risks that are reviewed and discussed in the monthly meetings;<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">continuous monitoring of progress on ESG best-practice engagement.<\/span><\/span><\/li>\n<\/ul>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund reports the attainment of the social characteristic it promotes:\u00a0<\/span><\/span><\/p>\n<ul>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">annually on the percentage of investee companies researching, developing, or producing treatment for diseases with a high unmet medical need;\u00a0<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">annually on the engagement priorities with investee companies using the findings from the ESG material risk analysis and the \u2018Do No Significant Harm\u2019 (<\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b>DNSH<\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">) analysis.\u00a0<\/span><\/span><\/li>\n<\/ul>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The companies the Fund invests in should not only have strong financials, good management and comply with the regulations, but they should also continue to improve their ESG performance wherever possible. The portfolio manager of the Fund has a long history of investing in and engaging with biotech companies. Engagement with small-cap companies can be very effective and can have a concrete and direct impact on their policies and practices.<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">More details can be found in the\u00a0<\/span><\/span><span style=\"color: #467886;\"><u><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_PCD_EN.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">SFDR Pre-Contractual Disclosure (Annex II)<\/span><\/span><\/a><\/u><\/span><span lang=\"en-US\">.<\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Methodologies<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><br \/>The Fund uses the following methodologies\u00a0to measure how investments contribute to the social characteristic of the Fund:<\/span><\/span><\/p>\n<ol style=\"list-style-type: lower-alpha;\" type=\"a\">\n<li>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund applies the materiality map of the SASB to determine which sustainability risks are material to consider in the investment decision-making process. SASB has identified more than 25 sustainability risks divided across the ESG topics. Dependent on the economic sector the investment is active in, these risks are marked either: not material, not likely material, or likely material. For a risk to be classified as likely material, SASB has found that for over 50 percent of the companies active in that sector, the risk has a significant impact on the financial position or operational activities. The Fund performs an analysis based on policies, practices, and incidents to determine if the investee company has a low, average or high estimated sensitivity of the value of the investment to material sustainability risks.<\/span><\/span><\/p>\n<\/li>\n<li>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund determines if a company qualifies to contribute to the attainment of the Fund\u2019s social characteristic if:<\/span><\/span><\/p>\n<ol style=\"list-style-type: lower-alpha;\" type=\"a\">\n<li>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">For a company with product(s) on the market that has been profitable in the past three years:\u00a0\u2265 50 percent of the products it markets are aimed at treating diseases with a high unmet medical need.<\/span><\/span><\/p>\n<\/li>\n<li>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">For an unprofitable company with product(s) on the market or for a company without product(s) on the market:\u00a0\u2265 50 percent of its pipeline programs and products on the market are aimed at treating diseases with a high unmet medical need.<\/span><\/span><\/p>\n<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">If a company qualifies, then the actual percentage of pipeline programs and\/or products on the market addressing a high unmet medical need will be used in the calculation of how much of the Fund\u2019s assets under management (<\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b>AUM<\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">) is contributing to this characteristic, proportionate to that company\u2019s weight in the portfolio. If a company does not qualify, then it counts for zero percent to the Fund\u2019s calculation of AUM contribution to the high unmet need goal.<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">More details can be found in the\u00a0<\/span><\/span><span style=\"color: #467886;\"><u><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_PCD_EN.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">SFDR Pre-Contractual Disclosure (Annex II)<\/span><\/span><\/a><\/u><\/span><span lang=\"en-US\">.<\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Data sources and processing<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b><br \/><\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund uses data for the following purposes:<\/span><\/span><\/p>\n<ul>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Sourcing of investee companies<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Monitoring sustainability risks<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Reporting on PAI indicators and engagement activities<\/span><\/span><\/li>\n<\/ul>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Data used and processed by the Fund to attain the social characteristic and report on PAI indicators are as follows:<\/span><\/span><\/p>\n<ol>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Sources:\u00a0Publicly available investee company financial data, company policies, annual reports and ESG ratings from third parties.\u00a0PAI indicators data are requested by the Fund to the investee company.<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Data quality:\u00a0A potential investee company needs to be willing to communicate and share information regarding the relevant topics and sustainability risk factors for the Fund\u2019s ESG policy.<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Data processing: the Fund processes data from investee companies via a software provider, checks the received data and does not process the data beyond preparing investor communications and regulatory reports.<\/span><\/span><\/li>\n<\/ol>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Limitations to methodologies and data<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><br \/>The Fund expects limitations to occur with the current methodologies and data collection as\u00a0investee companies may be subject to differing legislation and regulatory requirements.\u00a0As\u00a0reporting on sustainability issues matures,\u00a0the availability of data related to sustainability, the Fund\u2019s methodologies\u00a0and data sources\u00a0is expected to\u00a0improve.\u00a0<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Due diligence<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b><br \/><\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund follows the below investment processes, including due diligence on potential investments:<\/span><\/span><\/p>\n<ol>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Sector coverage: All companies in the biotechnology sector are reviewed annually using research, screening, data analysis and information gathered in the field.<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Identification of edge vs. the market: Using proprietary financial models as the basis of the Fund\u2019s expectation for a company, potential new investments are reviewed quarterly against market expectation.<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Investment thesis construction: Companies reviewed monthly to map to which extent they fit into the Fund\u2019s portfolio. A review of the contribution of the company to the Fund\u2019s social characteristic is part of this analysis.<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Continuous monitoring: Findings from the ESG material risk analysis and DNSH analysis are combined to inform the engagement priorities for an investee company.<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">All investments and their contribution to the Fund\u2019s social characteristic are audited annually by an external auditor.<\/span><\/span><\/li>\n<\/ol>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">More details can be found in the\u00a0Fund\u2019s <\/span><\/span><span style=\"color: #467886;\"><u><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/01\/AescapGen_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">prospectus<\/span><\/span><\/a><\/u><\/span><span lang=\"en-US\">.<\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Engagement policies<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b><br \/><\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">The Fund upholds the following approaches with regards to engagement with its investee companies:<\/span><\/span><\/p>\n<ol>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Contribution to the Fund\u2019s social characteristic: The investee company should not only have strong financials and good management, but they should also continue to improve their ESG performance wherever possible. On an ongoing basis, the sustainability risk analyses for the investments of the Fund are reviewed and updated when applicable. Material changes to the individual sustainability risks of an investment are not expected to occur often. In addition, the Fund excludes potential investments with a history of poor performance on sector best practice, that have insufficient policies, or that has insufficient plans to improve in their social and environmental impact.<\/span><\/span><\/li>\n<li class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Voting: As an active investor, the Fund regularly engages with its investee companies on a wide range of topics, including ESG. Through its regular monitoring and screening activities, engagement is initiated when the Fund identifies a concern. The Fund engages with an investee company through meetings and calls with the company\u2019s management, email communications with investor relations or company representatives on specific matters, company site visits, interactions with external industry experts or other industry participants, and formal shareholder voting.\u00a0\u00a0<\/span><\/span><\/li>\n<\/ol>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">Progress on the Fund\u2019s portfolio ESG performance and engagement activities is reported on in the Fund\u2019s PAI report.\u00a0\u00a0<\/span><\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">More details can be found in the\u00a0Fund\u2019s <\/span><\/span><span style=\"color: #467886;\"><u><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_PAI_Statement_EN.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\">PAI Report<\/span><\/span><\/a><\/u><\/span><span lang=\"en-US\">.<\/span><\/p>\n<p class=\"western\" lang=\"nl-NL\"><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><u>Designated reference benchmark<\/u><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><b>\u00a0<\/b><\/span><\/span><span style=\"font-family: Calibri, serif;\"><span lang=\"en-GB\"><br \/>The Fund\u202fdoes not compare its ESG performance to a\u202fbenchmark\u202for index.<\/span><\/span><\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2055\" aria-expanded=\"false\">Fund Documents<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2055\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"5\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-2055\" tabindex=\"0\" hidden=\"hidden\"><p><strong>Reporting<\/strong><\/p>\n<ul>\n<li><a style=\"font-size: 16px; background-color: #ffffff;\" href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/05\/AescapGen_ARPT_EN.pdf\">Annual Report 2024 Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2025\/04\/240430-Annual-Report-Aescap-Genetics.pdf\">Annual Report 2023 Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/04\/230430-Annual-Report-2022-Aescap-Genetics-Fund.pdf\">Annual Report 2022 Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/08\/AescapGen_SARPT_EN.pdf\">Interim Financial Statements 2025 Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2025\/08\/240820-Interim-Statements-2024-Aescap-Genetics.pdf\">Interim Financial Statements 2024 Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/08\/230817-Interim-Financial-Statements-2023-Aescap-Genetics.pdf\">Interim Financial Statements 2023 Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/01\/AescapGen_Article50.pdf\">Monthly NAV and performance statement Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2026\/03\/AescapGen_Manager_PastPerf_EN.pdf\" target=\"_blank\" rel=\"noopener\">Past Performance Presentation Unit Class Aescap Genetics &#8211; Manager (EN)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2026\/03\/AescapGen_Investors_PastPerf_EN.pdf\" target=\"_blank\">Past Performance Presentation Unit Class Aescap Genetics &#8211; Investors (EN)<\/a><\/li>\n<\/ul>\n<p><strong>Prospectus<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/01\/AescapGen_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener\">Prospectus Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/10\/AescapGen_SUPPL1_PROSP_EN.pdf\">Supplement to Prospectus Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/11\/AescapGen_EXPL_SUPPL1_PROSP_EN.pdf\">Explanation Supplement to Prospectus Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_PCD_EN.pdf\" target=\"_blank\" rel=\"noopener\">SFDR Pre-contractual disclosure document Aescap Genetics&nbsp;<\/a> (version 2.3, August 2024)<\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapGen_SFDR_PAI_Statement_EN.pdf\" target=\"_blank\" rel=\"noopener\">PAI Report 2024 Aescap Genetics<\/a><\/li>\n<\/ul>\n<p><strong>Key Information Document<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Manager_KID_EN.pdf\">KID Unit Class Aescap Genetics \u2013 Manager (EN)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Manager_KID_NL.pdf\">KID Unit Class Aescap Genetics \u2013 Manager (NL)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/01\/AescapGen_Investors_KID_EN.pdf\">KID Unit Class Aescap Genetics \u2013 Investors (ENG)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors_KID_NL.pdf\">KID Unit Class Aescap Genetics \u2013 Investors (NL)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors-10M_KID_EN.pdf\">KID Unit Class Aescap Genetics \u2013 Investors 10M+ (EN)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors-10M_KID_NL.pdf\">KID Unit Class Aescap Genetics \u2013 Investors 10M+ (NL)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors-20M_KID_EN.pdf\">KID Unit Class Aescap Genetics \u2013 Investors 20M+ (EN)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors-20M_KID_NL.pdf\">KID Unit Class Aescap Genetics \u2013 Investors 20M+ (NL)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors-30M_KID_EN.pdf\">KID Unit Class Aescap Genetics \u2013 Investors 30M+ (EN)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapGen_Investors-30M_KID_NL.pdf\">KID Unit Class Aescap Genetics \u2013 Investors 30M+ (NL)<\/a><\/li>\n<\/ul>\n<p><strong>Forms<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/06\/AescapGen_SUBFORM_EN.pdf\">Subscription form Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/06\/AescapGen_ADDL_SUBFORM_EN.pdf\">Additional Subscription Form Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/02\/AescapGen_REDFORM_EN.pdf\">Redemption form Aescap Genetics<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2019\/02\/190130-FATCA_CRS-individuals.pdf\">Self-certification form (individuals)<\/a><\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2019\/02\/190130-FATCA_CRS-Entities.pdf\">Self-certification form (entities)<\/a><\/li>\n<\/ul><\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-07dfce7 elementor-widget elementor-widget-image\" data-id=\"07dfce7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"300\" height=\"212\" src=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-300x212.jpg\" class=\"attachment-medium size-medium wp-image-21393\" alt=\"\" srcset=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-300x212.jpg 300w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-1024x723.jpg 1024w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-768x543.jpg 768w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-1536x1085.jpg 1536w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-2048x1447.jpg 2048w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-18x12.jpg 18w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-bc712de e-flex e-con-boxed e-con e-parent\" data-id=\"bc712de\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c986ce3 elementor-widget elementor-widget-template\" data-id=\"c986ce3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"template.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-template\">\n\t\t\t\t\t<div data-elementor-type=\"container\" data-elementor-id=\"19277\" class=\"elementor elementor-19277\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3643263 e-flex e-con-boxed e-con e-parent\" data-id=\"3643263\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d8d5ff3 elementor-widget elementor-widget-heading\" data-id=\"d8d5ff3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Examples of Funds and Strategies in the Netherlands<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5199201 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"5199201\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-e501c77 e-grid e-con-boxed e-con e-parent\" data-id=\"e501c77\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ad242b4 elementor-widget elementor-widget-image\" data-id=\"ad242b4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.priviumfund.com\/zh\/aescap-life-sciences\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1024\" height=\"691\" src=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Life-Siences-2022-1024x691.jpg\" class=\"attachment-large size-large wp-image-21395\" alt=\"\" srcset=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Life-Siences-2022-1024x691.jpg 1024w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Life-Siences-2022-300x202.jpg 300w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Life-Siences-2022-768x518.jpg 768w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Life-Siences-2022-1536x1036.jpg 1536w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Life-Siences-2022-2048x1381.jpg 2048w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Life-Siences-2022-18x12.jpg 18w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-09241f3 elementor-widget elementor-widget-image\" data-id=\"09241f3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.priviumfund.com\/zh\/aescap-genetics\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"300\" height=\"212\" src=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-300x212.jpg\" class=\"attachment-medium size-medium wp-image-21393\" alt=\"\" srcset=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-300x212.jpg 300w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-1024x723.jpg 1024w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-768x543.jpg 768w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-1536x1085.jpg 1536w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-2048x1447.jpg 2048w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/07\/Logo-Aescap-Genetics-2022-18x12.jpg 18w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3337f40 elementor-widget elementor-widget-heading\" data-id=\"3337f40\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h5 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/www.priviumfund.com\/zh\/aiconic-partners-fund\/\">Aiconic Partners Fund<\/a><\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3a178ea elementor-widget elementor-widget-image\" data-id=\"3a178ea\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.priviumfund.com\/zh\/dutch-mezzanine-fund-IV\/\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"558\" height=\"373\" src=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-23-at-11.46.22-AM.png\" class=\"attachment-large size-large wp-image-17409\" alt=\"\" srcset=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-23-at-11.46.22-AM.png 558w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-23-at-11.46.22-AM-300x201.png 300w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-23-at-11.46.22-AM-18x12.png 18w\" sizes=\"(max-width: 558px) 100vw, 558px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-823ca7e elementor-widget elementor-widget-image\" data-id=\"823ca7e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.priviumfund.com\/zh\/feo\/\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"103\" src=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2025\/10\/FF_Logo-Vertical_Tag_02_Transparente-300x103.png\" class=\"attachment-medium size-medium wp-image-24449\" alt=\"\" srcset=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2025\/10\/FF_Logo-Vertical_Tag_02_Transparente-300x103.png 300w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2025\/10\/FF_Logo-Vertical_Tag_02_Transparente-1024x353.png 1024w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2025\/10\/FF_Logo-Vertical_Tag_02_Transparente-768x265.png 768w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2025\/10\/FF_Logo-Vertical_Tag_02_Transparente-1536x530.png 1536w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2025\/10\/FF_Logo-Vertical_Tag_02_Transparente-2048x706.png 2048w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2025\/10\/FF_Logo-Vertical_Tag_02_Transparente-18x6.png 18w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-afe710c elementor-widget elementor-widget-image\" data-id=\"afe710c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.priviumfund.com\/zh\/fmo-privium-impact-fund\/\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"186\" src=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/10\/FMO-logo-300x186.png\" class=\"attachment-medium size-medium wp-image-13065\" alt=\"\" srcset=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/10\/FMO-logo-300x186.png 300w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/10\/FMO-logo-768x477.png 768w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/10\/FMO-logo-18x12.png 18w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/10\/FMO-logo.png 788w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-281d930 elementor-widget elementor-widget-image\" data-id=\"281d930\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.priviumfund.com\/zh\/guardian-fund\/\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"993\" height=\"192\" src=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2020\/12\/Guardian-logo.jpg\" class=\"attachment-large size-large wp-image-3629\" alt=\"\" srcset=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2020\/12\/Guardian-logo.jpg 993w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2020\/12\/Guardian-logo-300x58.jpg 300w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2020\/12\/Guardian-logo-768x148.jpg 768w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2020\/12\/Guardian-logo-16x3.jpg 16w\" sizes=\"(max-width: 993px) 100vw, 993px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7638440 elementor-widget elementor-widget-image\" data-id=\"7638440\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.priviumfund.com\/zh\/principia-fund\/\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"318\" height=\"80\" src=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/04\/Principia-Logo.png\" class=\"attachment-large size-large wp-image-20477\" alt=\"\" srcset=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/04\/Principia-Logo.png 318w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/04\/Principia-Logo-300x75.png 300w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/04\/Principia-Logo-18x5.png 18w\" sizes=\"(max-width: 318px) 100vw, 318px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2d57be6 elementor-widget elementor-widget-heading\" data-id=\"2d57be6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h5 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/www.priviumfund.com\/zh\/strategy-one-fund\/\">Strategy One Fund<\/a><\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-78c97c4 elementor-widget elementor-widget-heading\" data-id=\"78c97c4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h5 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/www.priviumfund.com\/zh\/tpm-privium-private-equity-program-2025\/\">TPM Privium Private Equity Program 2025<\/a><\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a9c95bc elementor-widget elementor-widget-image\" data-id=\"a9c95bc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.priviumfund.com\/zh\/tpm-privium-private-debt-portfolio\/\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"540\" height=\"354\" src=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/04\/TPM.png\" class=\"attachment-large size-large wp-image-21491\" alt=\"\" srcset=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/04\/TPM.png 540w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/04\/TPM-300x197.png 300w, https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/04\/TPM-18x12.png 18w\" sizes=\"(max-width: 540px) 100vw, 540px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>About Latest Report Request Information Sustainability-related Disclosures Fund Documents About Aescap Genetics\u00a0invests in the shares of publicly listed genetics biotech \/ life sciences companies. It invests in highly innovative companies that develop and market new genetics medical treatments such as gene, RNA and cell therapies. It can to a limited extent also invest in companies [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"full-width-container","site-content-style":"unboxed","site-sidebar-style":"unboxed","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-19489","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.priviumfund.com\/zh\/wp-json\/wp\/v2\/pages\/19489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.priviumfund.com\/zh\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.priviumfund.com\/zh\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.priviumfund.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.priviumfund.com\/zh\/wp-json\/wp\/v2\/comments?post=19489"}],"version-history":[{"count":33,"href":"https:\/\/www.priviumfund.com\/zh\/wp-json\/wp\/v2\/pages\/19489\/revisions"}],"predecessor-version":[{"id":25174,"href":"https:\/\/www.priviumfund.com\/zh\/wp-json\/wp\/v2\/pages\/19489\/revisions\/25174"}],"wp:attachment":[{"href":"https:\/\/www.priviumfund.com\/zh\/wp-json\/wp\/v2\/media?parent=19489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}